Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU410ST clinical trial recently convened and approved to proceed dosin ...

公司信息 - Ocugen公司将于2024年4月2日上午8:30在东部时间举行电话会议和网络直播，提供截至2023年12月31日的财务业绩更新[1] - 参与者可通过拨打电话号码(800) 715-9871（美国）和(646) 307-1963（国际）参与电话会议，会议ID为4947142[2] - Ocugen公司是一家专注于发现、开发和商业化新型基因和细胞疗法、生物制剂和疫苗的生物技术公司，致力于改善全球患者的健康并为他们带来希望[3]

Ocugen公司任命首席医疗官 - Ocugen公司宣布任命Dr. Huma Qamar为首席医疗官（CMO）[1] - Dr. Qamar在临床研究领域拥有丰富的背景，曾在耶鲁大学、哈佛大学和宾夕法尼亚大学等知名学府贡献专业知识[2] - Dr. Qamar在多个治疗领域具有专业知识，包括基因和细胞治疗、疫苗、肿瘤学、风湿病学、皮肤病学、神经学、心脏病学、肝病学和传染病等[3] Ocugen公司的专注领域 - Ocugen公司专注于发现、开发和商业化新型基因和细胞疗法，致力于改善全球患者的健康，通过创新科学路径对患者的生活产生影响[4]

MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). GA affects appro ...

MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ. "I look forward to joining my peers in discussing th ...

公司介绍 - Ocugen公司是一家专注于发现、开发和商业化新型基因和细胞疗法以及疫苗的生物技术公司[1] 突破性技术 - Ocugen公司的突破性修饰基因疗法平台有潜力用单一产品治疗多种视网膜疾病[4] 研究领域 - Ocugen公司在感染性疾病和骨科疾病领域的研究也在不断推进，以满足未满足的医疗需求[4]

MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the Abu Dhabi Family Office (ADFO) Summit being held February 29—March 1, 2024 at the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab Emirates. "I'm honor ...

Ocugen (NASDAQ:OCGN) stock fans will want to keep an eye on the clinical-stage biopharmaceutical company as it has big news coming on Wednesday.That’s when Ocugen plans to hold a Clinical Showcase covering the company’s upcoming Phase 3 trial of OCU400. The event is set to start at 10:00 a.m. Eastern Time tomorrow and will last until noon.To go along with this, the company says it will include details from its ongoing Phase 1/2 trial of OCU400 during that Clinical Showcase. All of this is related to OCU400’ ...

Ocugen公司临床展示活动 - Ocugen公司将于2024年2月21日在纽约市时代广场的纳斯达克市场举办临床展示活动，重点介绍OCU400第3期临床试验将于2024年初开始[1] - 临床展示活动将提供了解OCU400第3期试验的机会，包括研究设计的具体细节和治疗遗传性视网膜色素变性的广泛适应症，以及OCU400正在进行的第1/2期试验的临床研究更新[2] - Ocugen公司的演讲者包括董事长、首席执行官和联合创始人Shankar Musunuri博士，高级副总裁Mike Shine，首席科学官兼研发负责人Arun Upadhyay博士等[3] - 临床展示活动还将邀请包括眼科学副教授Lejla Vajzovic博士、眼科学教授Byron Lam博士、Harvard医学院教师Neena Haider博士等在内的专家参与讨论[3]

MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will give the keynote: Future Innovations in Healthcare: From Dreaming to Community Health at the Pharma Market Research Conference (PMRC) from February 7-8, 2024 in Newark, NJ. "Since its beg ...